Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving oxidoreductase
Reexamination Certificate
2005-10-04
2009-12-08
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving oxidoreductase
C435S069200
Reexamination Certificate
active
07629140
ABSTRACT:
A Rapid And Sensitive Radiometric Assay For Assessing The Activity Of Cytochrome P-450 (CYP) 2C9 And The Potential Of An Analyte To Inhibit CYP2C9 Activity Or Induce CYP2C9 Expression is described. All the steps of the assay, including incubations, product separation, and radioactivity counting are preferably performed in a multiwell format, which can be automated.
REFERENCES:
patent: 6338802 (2002-01-01), Bodner et al.
patent: 6491873 (2002-12-01), Roberts et al.
patent: 6506343 (2003-01-01), Bodner et al.
patent: 6726842 (2004-04-01), Bouvier et al.
patent: 2003/0143124 (2003-07-01), Roberts et al.
patent: 2003/0195350 (2003-10-01), Leyland-Jones
patent: 2004/0043377 (2004-03-01), Shimada et al.
patent: 2008/0145886 (2008-06-01), Laufer et al.
patent: WO 97/38774 (1997-10-01), None
patent: WO 2005/098025 (2005-10-01), None
Sioufi A. et al. Determination of Diclofenac in Plasma and Urine . . . J of Chromatography 571:87-100, 1991.
Bachmann et al., Current Drug Metab . . , vol. 2 (2001), pp. 299-314, “The use of in vitro methods to predict in vivo pharmacokinetics . . . ”.
Bourrie et al., J. Pharmacol. & Exper. Ther., vol. 277 (1996), pp. 321-332, “Cytochrome P450 isoform inhibitors as a tool for the investigation . . . ”.
Cohen et al., Drug Metab. & Disposition, vol. 31 (2003), pp. 1005-1015, “In vitro drug interactions of cytochrome P450: an evaluation . . . ”.
Crespi et al., J. Pharmacol. & Toxicol. Methods, vol. 44 (2000), pp. 325-331, “Fluorometric screening for metabolism-based drug-drug interactions”.
Eagling et al., Br. J. Clin. Pharmacol., vol. 45 (1998), pp. 107-114, “Differential selectivity of cytochrome P450 inhibitors against probe substrates . . . ”.
Egnell et al., J. Pharmacol. & Exper. Ther., vol. 307 (2003), pp. 878-887, “Generation and evaluation of a CYP2C9 heteroactivation pharmacophore”.
Goldstein et al., Br. J. Clin. Pharmacol., vol. 52 (2001), pp. 349-355, “Clinical relevance of genetic polymorphisms in the human CYP2C subfamily”.
Hengstler et al., Drug Metab. Rev., vol. 32, pp. 81-118, “Cryopreserved oprimary hepatocytes as a constantly available in vitro model . . . ”.
Hummel et al., Biochemistry, vol. 43 (2004), pp. 7207-7214, “Effector-mediated alteration of substrate orientation in cytochrome P450 2C9”.
Hutzler et al., Arch. Biochemistry & Biophysics, vol. 410 (2003), pp. 16-34, “Activation of cytochrome P450 2C9-mediated metabolism: . . . ”.
Ito et al., Br. J. Clin. Pharmacol., vol. 57 (2004), pp. 473-486, “Database analyses for the prediction of in vivo drug-drug interactions from in vitro data”.
Korzekwa et al., Biochemistry, vol. 37 (1998), pp. 4137-4147, “Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates . . . ”.
Lin et al., Clin. Pharmacokinet., vol. 34 (1998), pp. 361-390, “Inhibition and induction of cytochrome P450 and the clinical implications”.
Mei et al., J. Pharmacol. & Exper. Ther., vol. 291 (1999), pp. 749-759, “Role of a potent inhibitory monoclona antibody cytochrome P-450 3A4 . . . ”.
Miners et al., Br. J. clin. Pharmacol., vol. 45 (1998), pp. 525-538, “Cytochrome P4502C9: an enzyme of major importance in human drug . . . ”.
Moser et al., J. Med. Chem., vol. 33 (1990), pp. 2358-2368, “Synthesis and quantitative structure—activity relationships . . . ”.
Oza et al., J. Med. Chem., vol. 45 (2002), pp. 321-332, “Synthesis, structure, and activity of diclofenac analgoues as . . . ”.
Satoh et al., J. Med. Chem., vol. 36 (1993), pp. 3580-3594, “Substituted chromenes as potent, orally active 5-lipoxygenase . . . ”.
Schwarz, Eur. J. Clin. Investig., vol. 33 (2003), pp. 23-30, “Clinical relevance of genetic polymorphisms in the human CyP2C9 gene”.
Shou et al., Eur. J. Pharmacol., vol. 394 (2000), pp. 199-209, “Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 . . . ”.
von Moltke et al., Biochem. Pharmacol., vol. 55 (1998), pp. 113-122, “In vitro approaches to predicting drug interactions in vivo”.
Xie et al., Adv. Drug Delivery Rev., vol. 54 (2002), pp. 1257-1270, “CYP2C9 allelic variants: ethnic distribution an functional . . . ”.
Riley, Curr. Opin. in Drug Discovery & Develop., vol. 4 (2001), pp. 45-54, “The potential pharmacological an toxicological impact . . . ”.
Thummel et al., Ann. Rev. Pharmacol. Toxicol., vol. 38 (1998), pp. 389-430, “In vitro and in vivo drug interadtions involving human CYP3A”.
Guengerich, Cytochromes P450: Metabolic & Toxicological Aspects, Chapter 3, pp. 55-74, “The chemistry of cytochrome P450 reactions”.
Ioannides et al., Cytochromes P450: Metabolic & Toxicological Aspects, Chapter 12, pp. 301-327, “Expression of cytochrome P450 proteins in disease”.
Lewis, Cytochromes P450: Metabolic & Toxicological Aspects, Chapter 14, pp. 355-398, “Molecular modeling of mammalian cytochromes P450”.
Dich et al., Methods in Molecular Biology, vol. 5: Animal Cell Culture (1989), pp. 161-176, “Primary cultures of rat hepatocytes”.
Bertz et al., Clin. Pharmacokinet., vol. 32 (1997), pp. 210-258, “Use of in vitro and in vivo data to estimate the likelihood of metabolic . . . ”.
Guengerich, Ann. Rev. Pharmacol. & Toxicology, vol. 39 (1999), pp. 1-17, “Cytochrome P-450 3A4: Regulation and role in drug metabolism”.
Northrop, Meth. Enzymol., vol. 87 (1982), pp. 607-625, “Deuterium and tritium isotope effects on initial rates”.
Ferrini et al., Methods in Molec. Biol., vol. 107: Cytochrome P450 Protocols (1998), pp. 341-352, Human hepatocyte culture.
De Lean et al., The Receptors: A Comprehensive Treatise, vol. 1 (1979), p. 143-192, “Kinetics of cooperative binding”.
Chaudhary Ashok
Di Marco Annalise
Laufer Ralph
Fitch Catherine D.
Gitomer Ralph
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.
Reilly John David
LandOfFree
Assay for cytochrome P450 isoform 2C9 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay for cytochrome P450 isoform 2C9, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay for cytochrome P450 isoform 2C9 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105947